ALLO

Allogene Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.83

Price (1 Year)

$2.78 $0.83

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30
Non-compliant assets / Total market cap %78.6 / %30
Non-compliant revenue / Total income %73.8 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.

Website

Analysis (Turkish): ALLO Hissesi Caiz mi, Helal mi? Allogene Therapeutics, Inc. Katılım Analizi